A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Sirukumab (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 28 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 18 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.